Haloperidol for Hypoactive and Hyperactive Delirium in ICU Patients-A Post Hoc Bayesian Analysis of the AID-ICU Trial.
Acta Anaesthesiol ScandSep 19, 2026
Nina C Andersen-Ranberg, Lone Musaeus Poulsen, Anders Perner et al.
✦ AI-curated · Sources linked
In 30 seconds
This post hoc analysis of the AID-ICU trial evaluated the effects of haloperidol on delirium subtypes in 987 ICU patients. Haloperidol was linked to more days alive out of hospital, with a 76.5% probability of greater benefit in hyperactive delirium (mean difference 2.9 days).
Key findings
- Haloperidol increased days alive out of hospital by 2.9 days in hyperactive delirium patients.
- There was a 73% probability of lower mortality in patients with hyperactive delirium receiving haloperidol.
- Haloperidol showed no significant differences in serious adverse reactions or rescue medication use.
Why it matters
Understanding the differential effects of haloperidol on delirium subtypes can guide treatment decisions in ICU settings, potentially improving patient outcomes and reducing mortality.